Anti-Human IL17A Therapeutic Antibody (Secukinumab) (CAT#: TAB-069)

Recombinant monoclonal antibody to IL17A. Secukinumab is a human monoclonal antibody designed for the treatments of uveitis, rheumatoid arthritis, and psoriasis. It targets member A from the cytokine family of interleukin 17.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Datasheet
  • MSDS
  • COA
IHC

Figure 1 The Immunostaining of IL17 receptors are expressed in human astrocytes.

Scale bar 20 um, Hoechst was used as nuclear stain.

Elain, G., Jeanneau, K., Rutkowska, A., Mir, A. K., & Dev, K. K. (2014). The selective anti‐IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A‐induced levels of IL6 in human astrocytes. Glia, 62(5), 725-735.

FC

Figure 2 FACs analysis of IL17 receptors are expressed in human astrocytes.

The data showed expression of IL17RA and IL17RC in human astrocytes.

Elain, G., Jeanneau, K., Rutkowska, A., Mir, A. K., & Dev, K. K. (2014). The selective anti‐IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A‐induced levels of IL6 in human astrocytes. Glia, 62(5), 725-735.

ELISA

Figure 3 ELISA analysis of IL17A expression in mouse astrocytes.

IL17A increases the levels of IL6 in mouse astrocytes.

Elain, G., Jeanneau, K., Rutkowska, A., Mir, A. K., & Dev, K. K. (2014). The selective anti‐IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A‐induced levels of IL6 in human astrocytes. Glia, 62(5), 725-735.

IF

Figure 4 Effects of Secukinumab on IL17A/TNFa-induced NF-jB activation.

The differences between treated and nontreated cells can be more easily seen in the black
and white "co-localizing pixels" where only the nuclei can be seen and the intensity of white is proportional to the amount of NFkB
present in these nuclei.

Elain, G., Jeanneau, K., Rutkowska, A., Mir, A. K., & Dev, K. K. (2014). The selective anti‐IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A‐induced levels of IL6 in human astrocytes. Glia, 62(5), 725-735.


Specifications

  • Immunogen
  • HuIL-17 coupled 10 KLH mixed 1:1 with huIL-17 in Gerbu adjuvant.
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG1 - kappa
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • IF, IHC, ELISA, FC
  • Trade name
  • Cosentyx
  • CAS
  • 875356-43-7
  • Generic Name
  • Secukinumab
  • ATC Code
  • L04AC10
  • DrugBank
  • DB09029
  • MW
  • 147.94 kDa
  • Related Disease
  • Psoriatic arthritis (PSA)

Applications

  • Application Notes
  • The IL17A antibody has been reported in applications of Immunofluorescence, Immunohistochemistry, Enzyme-linked Immunosorbent Assay, Flow Cytometry. FC: The isotype, IL17RA AlexaFluor 647 and IL17RC AlexaFluor 488 antibodies were used at 4mg/ml and 10mg/ml respectively for FACs analysis.

Target

  • Alternative Names
  • Secukinumab;Cosentyx;875356-43-7;AIN457;DB09029IL17A;interleukin 17A;CTLA8, IL17, interleukin 17 (cytotoxic T lymphocyte associated serine esterase 8);interleukin-17A;cytotoxic T lymphocyte associated protein 8;IL 17;IL 17A;CTLA-8;cytotoxic T-lymphocyte-a

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Resources

Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Secukinumab.

See other products for "Secukinumab"

Afuco™ Anti-IL17A ADCC Therapeutic Antibody (Secukinumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL17A. Secukinumab is a human monoclonal antibody designed for the treatments of uveitis, rheumatoid arthritis, and psoriasis. It targets member A from the cytokine family of interleukin 17.

See other products for "IL17A"


For Research Use Only. Not For Clinical Use.

* Abbreviations
3D IHC3D Immunohistochemistry
ActivActivation
AgonistAgonist
ApopApoptosis
BABioassay
BIBioimaging
BlockBlocking
Cell ScreeningCell Screening
SeparationCell Separation
ChIPChromatin Immunoprecipitation
CMCDComplement Mediated Cell Depletion
CostimCostimulation
CytCytotoxicity
DepletionDepletion
DBDot Blot
EMElectron Microscopy
ELISAEnzyme-linked Immunosorbent Assay
ELISPOTEnzyme-linked Immunosorbent Spot
FCFlow Cytometry
FuncSFunctional Assay
GSGel Super Shift Assay
HAHemagglutination
IAImmunoassay
IBImmunoblotting
ICCImmunocytochemistry
IDImmunodiffusion
IFImmunofluorescence
IHCImmunohistochemistry
IHC-FrImmunohistochemistry-Frozen
IHC-PImmunohistochemistry-Paraffin
REImmunohistology - Resin Sections
IPImmunoprecipitation
IRMAImmunoradiometric Assay
SHIn situ hybridization
InhibInhibition
ICFCIntracellular Staining for Flow Cytometry
KO/KD-WBKnockout/Knockdown target confirmation by Western Blot
Live cell imagingLive cell imaging
CyTOF®Mass Cytometry
MeDIPMethylated DNA Immunoprecipitation
MultiplexMultiplex bead-based assay
NeutNeutralization
PPProtein Purification
PGProteogenomics
RIRadial Immunodiffusion
RIARadioimmunoassay
StimStimulation
SPRSurface Plasmon Resonance
TCTissue Culture
TBTurbidimetry
WBWestern Blot

Send Inquiry

© 2022 Creative BioLabs. All Rights Reserved
  • 0
  • 0

Cart